Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04466150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04466150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Lead sponsor
University of California, San Francisco
Phase
Phase 4
Overall status
Active, not recruiting
Start date
August 30, 2020
Completion date
July 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinically isolated syndrome, relapsing multiple sclerosis